Related Experiment Video
Updated: Jun 4, 2025

Screening Bioactive Nanoparticles in Phagocytic Immune Cells for Inhibitors of Toll-like Receptor Signaling
Published on: July 26, 2017
Novel Triazines as NLRP3 Inhibitors for Treating Multiple Diseases
1Smith, Gambrell & Russell LLP, 1105 W. Peachtree Street NE, Suite 1000, Atlanta, Georgia 30309, United States.
Novel triazine compounds are introduced as inhibitors of the NLRP3 inflammasome. These compounds offer potential therapeutic applications for various diseases by modulating NLRP3 activity.
Area of Science:
- Medicinal Chemistry
- Immunology
- Pharmacology
Background:
- The NLRP3 inflammasome plays a critical role in inflammatory diseases.
- Targeting NLRP3 offers a promising therapeutic strategy for numerous conditions.
Related Concept Videos
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
NF-κB-dependent Signaling Pathway
NF-κB-dependent Signaling Mechanism
The...
Inflammatory Bowel Disease IV: Pharmacological Management
Pharmacologic...
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Targeted Cancer Therapies
There are several types of targeted therapies against...

